טרפרוסטיניל טבע 5 מ"ג/מ"ל - Treprostinil teva 5 mg/ml
× ×ª×× × ×ª×¨×פ×
| ××× ×× ×× × ×ספ×× |
| ||||||
|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | B01AC Platelet aggregation inhibitors excluding heparin | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | תת-×¢×ר×, ת××-×ר××× - S.C, I.V | ||||||
| צ×רת ××× ×× | ת×××¡× ×××רק×\××× ×¤××××, SOLUTION FOR INJECTION / INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | Treprostinil Teva is indicated for the treatment of:- Primary pulmonary arterial hypertension - Pulmonary arterial hypertension associated with connective tissue disorders.- Pulmonary hypertension associated with congenital systemic to pulmonary shunts. | ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×רפר×ס××× ×× ×××¢ 5 ×"×/×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL |
| ×©× ××¢× ×ר×ש×× | ABIC MARKETING LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 12/2019. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | {{{ת×ר×× ×¢××××}}} |
השינוי האחרון נעשה בֹ־23 בפברואר 2024 ב־12:14